This thesis, titled "Recent Advances in Pharmacotherapy for Colorectal Cancer," explores the latest developments in the treatment of colorectal cancer through pharmacological interventions. It provides a detailed review of recent innovations, including new targeted therapies such as anti-EGFR and anti-VEGF agents, and the introduction of immune checkpoint inhibitors. The thesis examines how these advancements have enhanced treatment efficacy and addressed issues of drug resistance. It also highlights the integration of these therapies into clinical practice and their impact on personalized treatment approaches. The analysis is supported by recent clinical trial data, offering a thorough understanding of current advancements. Overall, the thesis presents a critical evaluation of evolving pharmacotherapy strategies in colorectal cancer and outlines future directions for research.